The Top 5 Biosimilar Articles for the Week of January 25
Here are the top 5 biosimilar articles for the week of January 25, 2021.
Vizient Predicts 7.5% Humira Price Increase Before Biosimilars Arrive
In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace.
Nurses Can Counter Nocebo Effect in Biosimilar Switching
The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.
China Pulls Out Stops for Biosimilar Development
It took Henlius years to get a rituximab biosimilar approved in China. Now, that process could be cut in half, owing to significant regulatory reforms.
Investigators Weigh Differences in Biosimilar Quality Reporting
Consistency of reporting quality attributes for biosimilars may differ, complicating the job of getting a full picture of biosimilarity.
The Top 5 Biosimilar Articles for the Week of January 18
Here are the top 5 biosimilar articles for the week of January 18, 2021.
Coherus CEO Discusses Post–COVID-19 Growth Prospects
Coherus BioSciences CEO Dennis M. Lanfear discusses the company's biosimilar marketing prospects in 2021.
Prestige Biopharma Plots Biosimilar Growth Strategy
Biosimilars will be the cornerstone for a leap into biologics development and commercialization, according to the CEO of Prestige Biopharma. Also, Innovent Biologics reaches a marketing agreement.
Poll: Which of the following is true about insulin products and the BPCIA?
Many patient advocates hope that expansion of the Biologics Price Competition and Innovation Act (BPCIA) will bring further competition to the insulin market—and lower prices.
Investigators Study Risks of Hypertension, Proteinuria With Bevacizumab
The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.
Swift Uptake for Mvasi Suggests Provider Comfort With Use
Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.
IGBA, Celltrion, Others Mark Biosimilar Advances
The Center for Biosimilars® reports on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.
Opinion: Is the Ophthalmology Market Ready to Embrace Biosimilars?
Samsung Bioepis has filed for FDA approval for a ranibizumab biosimilar candidate (SB11), and more ophthalmology biosimilars are in the pipeline.
With New Policy, CMS Promises to Exit "Stone Age" of Health Information
CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.
The Top 5 Biosimilar Articles for the Week of January 11
Here are the top 5 biosimilar articles for the week of January 11, 2021.
Infliximab Biosimilar Switching Study Yields Evidence of Safety, Efficacy
A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.
Study: Machine Learning Could Optimize Biosimilar Therapy
Authors of a new study conclude that artificial intelligence could improve the selection of biosimilars for therapy.
Data From HERITAGE Confirm PK Biosimilarity for Ogivri
Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.
The Top 5 Biosimilar Articles for the Week of January 4
Here are the top 5 biosimilar articles for the week of January 4, 2021.
Economists Probe Cost-Effectiveness of Biosimilars
Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.
Adalimumab Biosimilars Face Product Obsolescence Before Launch
Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.
Investigators Chart ABP 980 Biosimilar Uptake in European Clinics
Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
Alvotech Breaks Ground for Biosimilar Development Facility
An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.
Reviewers Consider "Totality of Evidence" for Mvasi
Providers should feel confident using Mvasi, a bevacizumab biosimilar, for all indications of the reference product (Avastin), reviewers stated.
Innovent Biologics Gains NMPA Approval for Additional Sulinno Indications
China's National Medical Products Administration (NMPA) has cleared Innovent Biologics' adalimumab biosimilar for more indications.
The Leading “Not So Different” Podcast Episodes of 2020
Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Opinion: The Year Ahead in Biosimilar Potential
Many firsts may be in store for the biosimilar industry in 2021, although it will be dogged by ongoing difficulties, Center for Biosimilars® Advisory Board members said.
CfB Board Members Reflect on Year in Biosimilars
Incremental gains in the number of approved biosimilars and no new biologic categories were the low points, but uptake and improved patient access were highlights of 2020.
Pandemic Delays FDA Decision on Biocon's Bevacizumab Application
MYL-14020 could have been the fourth US biosimilar approved by the end of 2020, but the FDA hasn't been able to complete a necessary foreign inspection, owing to the pandemic.
The Most-Popular Center for Biosimilars® Interviews of 2020
Here are some of our most-popular biosimilar interviews for all of 2020.